DUBLIN — A blend of antibody drugs has proven effective among vulnerable patients showing symptoms of Covid-19, according to the Mayo Clinic.
Published by The Lancet, a British medical journal, the findings show a combination of casirivimab and imdevimab drugs help ensure “high-risk patients” do not need hospitalisation if hit with “mild to moderate Covid-19.”
The clinic gave the drugs, described as “monoclonal antibody treatments under Food and Drug Administration (FDA) emergency use authorization,” to almost 700 patients out of 1,400 enrolled in the study. 1.6 per cent of recipients were in hospital 28 days later along with 4.8 per cent of non-recipients, the medics reported.
“Once again, this real-world study suggests that when patients who are at high risk due to a range of co-morbidities contract a mild or moderate case of Covid-19, this combination of monoclonal injections gives them a chance of a non-hospitalized recovery,” said Raymund Razonable, an infectious diseases specialist with the clinic.
Former US president Donald Trump was given a similar cocktail, which he called “a cure,” after showing symptoms of Covid-19 before his election loss to Joe Biden last year.
The drug, developed by US pharma giant Regeneron and Switzerland’s Roche and known as Ronapreve, was last week approved by Britain’s regulator, which described it as “an important option in treatment to reduce the impact of Covid-19 in high-risk patients.”
Other treatments, such as the widely-used steroid Dexamethasone, which Britain’s Health Minister Sajid Javid described last week as “life saving,” have proven effective in treating serious cases of Covid-19.Show